Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722410 | 1.00 | TSHR (0.48) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4761853 | 1.00 | TSHR (0.48) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL1314862 | 0.97 | TSHR (0.46) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL4415250 | 0.97 | TSHR (0.46) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL18954375 | 0.97 | TSHR (0.46) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL23844021 | 0.83 | GRIN2D (0.39) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL16181835 | 0.83 | GRIN2D (0.35) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30338407 | 0.83 | GRIN2D (0.39) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5604725 | 0.82 | GRIN2D (0.37) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL8409549 | 0.82 | TSHR (0.46) | TSHRALDH1A1SLC7A5SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Pharmaceuticals, Inc. | 2022-02-03 | — | — | US | claimed |
| EP-3894395-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen BioPharma, Inc. (US) | 2021-10-20 | — | — | EP | claimed |
| WO-2020121123-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | claimed |
| CN-107849071-A | antiviral β amino acid ester phosphorodiamidate compounds | 默沙东公司 | 2018-03-27 | — | — | CN | claimed |
| EP-4209498-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Pharmaceuticals, Inc. | 2022-02-03 | — | — | US | disclosed |
| EP-3894395-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen BioPharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021149814-A1 | CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND | 学校法人中部大学 | 2021-07-29 | — | — | WO | disclosed |
| EP-3781584-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3390413-B1 | ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2020121123-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2019204637-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | SOUTHERN RESEARCH INSTITUTE (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-0946499-A1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Athena Neurosciences, Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998038177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE | ELAN PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998022430-A9 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998022430-A1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998022433-A1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | PNP, TYMP, HAVCR2 | TSHR 4265/4885ALDH1A1 2803/4885GRIN2D 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.